OncoCyte Corporation (NYSEMKT:OCX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 – Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers

Executive Compensation

On March 6, 2017, our Board of Directors, based on
recommendations of its Compensation Committee, set new annual
salaries for, and approved the payment of cash bonuses to,
certain OncoCyte executive officers, including those shown in the
following table.

About OncoCyte Corporation (NYSEMKT:OCX)

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.

OncoCyte Corporation (NYSEMKT:OCX) Recent Trading Information

OncoCyte Corporation (NYSEMKT:OCX) closed its last trading session down -0.25 at 5.05 with 48,783 shares trading hands.